Compare ZVIA & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZVIA | FBIO |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.4M | 88.7M |
| IPO Year | 2021 | N/A |
| Metric | ZVIA | FBIO |
|---|---|---|
| Price | $2.29 | $3.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $4.89 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 949.6K | 524.3K |
| Earning Date | 11-05-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $162,849,000.00 | $62,303,000.00 |
| Revenue This Year | $7.60 | $29.71 |
| Revenue Next Year | $6.70 | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.17 | N/A |
| 52 Week Low | $1.88 | $1.33 |
| 52 Week High | $4.99 | $4.20 |
| Indicator | ZVIA | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | 33.21 | 72.71 |
| Support Level | $2.54 | $3.31 |
| Resistance Level | $2.69 | $3.70 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 11.70 | 91.84 |
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.